If the cells you would like to access are currently listed as unavailable
or you are ordering from outside of Europe please get in touch via
Contact@EBiSC.org.
BIONi010-C-50
BIONi010-C + synapsin-m2rtTA + SNCA-A53T
Gene-edited iPSC line
A CLIP contains information about a cell line including any
specific third party obligations relating to, for example,
licensing obligations or the donor consent which affect the
use of the cell line.
The EBiSC Access and Use Agreement must be completed along with an individual
Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org
for countersignature. The EAUA must be fully signed before proceeding with your order.
To receive the Certificate of Analysis, please contact us.
A batch specific Certificate of Analysis will be available to
download once you receive your EBiSC iPSC line.
General#
Cell Line |
|
| hPSCreg name | BIONi010-C-50 |
| Alternative name(s) |
BIONi010-C + synapsin-m2rtTA + SNCA-A53T
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
BIONi010-C (BIONi010-C, K3P53) BIONi010-C-13 (BIONi010-C + NGN2 #I7-26) BIONi010-C-3 (BIONi010-C ApoE KO #KO30 P30) BIONi010-C-15 (BIONi010-C +dox inducible NGN2-GFP) BIONi010-C-25 (BIONi010-C heterozygous TREM2 KO) BIONi010-C-17 (BIONi010-C TREM2 KO) BIONi010-C-2 (BIONi010-C ApoE E3/E3 #H8 P32) BIONi010-C-6 (BIONi010-C ApoE E2/E2) BIONi010-C-7 (BIONi010-C Trem2 R47H) BIONi010-C-8 (BIONi010-C Trem2 T66M, #Y5-80) BIONi010-C-9 (BIONi010-C CD33 KO) BIONi010-C-70 (BIONi010-C with an APOE 2/2 genotype with an additional, homozygous christchurch mutation) BIONi010-C-71 (BIONi010-C with an APOE 3/3 genotype with an additional, homozygous christchurch mutation) BIONi010-C-4 (BIONi010-C ApoE E4/E4 #B44 P27) BIONi010-C-5 (BIONi010-C CD33 E2del #N14 P26) BIONi010-C-51 (BIONi010-C TNNI3-mCherry reporter) BIONi010-C-18 (BIONi010-C TBK1 KO) BIONi010-C-19 (BIONi010-C IKBKE KO) BIONi010-C-10 (HNF1AP291fsinsC +/- 54-5) BIONi010-C-11 (HNF1AP291fsinsC -/- 66-1) BIONi010-C-12 (HNF4ApR309C -/- 2-4) BIONi010-C-52 (BIONi010-C with an APOE 2/2 genotype (with two functional alleles in contrast to BIONi010-C-6)) BIONi010-C-53 (BIONi010-C with an APOE 3/3 genotype (with two functional alleles in contrast to BIONi010-C-2)) BIONi010-C-55 (BIONi010-C TNNI3-mCherry/TNNI1-EGFP dual reporter cl. 74) BIONi010-C-24 (BIONi010-C Dox a-syn) BIONi010-A (K1P53) BIONi010-B (K2P53, BIONi010-B) |
| Notes | This line contains the tetracycline transactivator m2rtTA under a human synapsin promoter on one allele of the AAVS1 locus and a cDNA of A53T SNCA on the other allele. When differentiated to neurons, the m2rtTA will be expressed. DOX needs to be added to have SNCA-A53T expression. SNCA-A53T should then only be expressed in neurons. |
Provider |
|
| Depositor | Bioneer (BION) |
| Owner | Bioneer (BION) |
| Distributors |
Bioneer (BION)
EBiSC
|
| Derivation country | Denmark |
External Databases |
|
| hPSCreg | BIONi010-C-50 |
| BioSamples | SAMEA7111003 |
General Information |
|
| This EBiSC line can be used for: |
Yes
Research use: allowed
Clinical use: no
Commercial use: no
|
| Subclone of | |
Donor Information#
General Donor Information |
|
| Sex | male |
| Ethnicity | Black or African-American |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA3105780 |
hIPSC Derivation#
General |
|
|
The source cell information can be found in the parental cell line
BIONi010-C.
|
|
| Passage number reprogrammed | 27 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Methods used |
PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions#
The following are the depositor culture conditions, they do not refer to any specific batch.
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 20 % |
| CO2 Concentration | 5 % |
| Medium |
mTeSR™ 1
|
Characterisation#
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|||||
| SOX2 |
Yes |
|||||
| TRA 1-81 |
Yes |
|||||
| SSEA-4 |
Yes |
Method documentation
Differentiation Potency
In vitro directed differentiation
| Marker | Expressed |
| CXCR4 |
Yes |
| SOX17 |
Yes |
Morphology
In vitro directed differentiation
| Marker | Expressed |
| CD34 |
Yes |
| NCAM1 |
Yes |
Morphology
In vitro directed differentiation
| Marker | Expressed |
| SOX1 |
Yes |
| PAX6 |
Yes |
Morphology
Genotyping#
Karyotyping (Cell Line) |
|
Other Genotyping (Cell Line) |
Genetic Modification#
| Genetic modifications not related to a disease |
|